Medical Device Company Brainsway Wants to Raise $30 Million on Nasdaq

Jerusalem-headquartered Brainsway develops headsets that use magnetic stimulation to treat brain disorders

Israeli medical device company Brainsway Ltd. wants to raise $30 million via a Nasdaq initial public offering under the ticker BWAY, according to a prospectus submitted to the U.S. Securities and Exchange Committee Monday. The sole underwriter is Cantor Fitzgerald & Co.

 

For daily updates, subscribe to our newsletter by clicking here.

 

Founded in 2003 with offices in Jerusalem and the U.S., Brainsway develops headsets that use magnetic stimulation to treat brain disorders. Its device has received approval in the European Union for various disorders including stroke rehabilitation, PTSD, Alzheimer's disease, and smoking cessation, and for depression and obsessive-compulsive disorder (OCD) in the U.S.

 

Nasdaq. Photo: Shutterstock

 

 

The company has been listed on the Tel Aviv Stock Exchange since 2010. That same year, Brainsway announced plans to list on Nasdaq, which it later withdrew.

 

Related stories:

• FDA Approves Brainsway’s Magnetic Stimulation Headset for OCD Treatment
• Cancer Treatment Company Anchiano Therapeutics Wants to List on Nasdaq
• Lottery Operator Tenlot Plans a Mid-2019 Stockholm IPO

 

 

Brainsway reported unaudited revenues of $11.6 million for the nine months ended September 30, 2018, and a total operating loss of $3.36 million.

 

The company intends to use the proceeds for general corporate purposes, for clinical trials, and to repay outstanding loans.